Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis.

Peroni S, Sorosina M, Malhotra S, Clarelli F, Osiceanu AM, Ferrè L, Roostaei T, Rio J, Midaglia L, Villar LM, Álvarez-Cermeño JC, Guaschino C, Radaelli M, Citterio L, Lechner-Scott J, Spataro N, Navarro A, Martinelli V, Montalban X, Weiner HL, de Jager P, Comi G, Esposito F, Comabella M, Martinelli-Boneschi F.

Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428. [Epub ahead of print]

PMID:
31221001
2.

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.

Clarelli F, Liberatore G, Sorosina M, Osiceanu AM, Esposito F, Mascia E, Santoro S, Pavan G, Colombo B, Moiola L, Martinelli V, Comi G, Martinelli-Boneschi F.

Pharmacogenomics J. 2017 Jan;17(1):84-91. doi: 10.1038/tpj.2015.85. Epub 2015 Dec 8.

PMID:
26644207
3.

A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.

Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, Pertel T, Stankiewicz JM, Martinelli V, Rodegher M, Weiner HL, Brassat D, Benoist C, Patsopoulos NA, Comi G, Elyaman W, Martinelli Boneschi F, De Jager PL.

Ann Neurol. 2015 Jul;78(1):115-27. doi: 10.1002/ana.24429. Epub 2015 May 14.

PMID:
25914168
4.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
5.

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL.

PLoS One. 2008 Apr 2;3(4):e1927. doi: 10.1371/journal.pone.0001927.

7.

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.

Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL.

Genes Immun. 2011 Sep;12(6):466-72. doi: 10.1038/gene.2011.18. Epub 2011 Apr 7. Erratum in: Genes Immun. 2012 Jul, 13(5):443. van der PouwKraan, T C T M [corrected to van der Pouw Kraan, TCTM].

PMID:
21471993
8.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
9.

Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge.

Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS.

Expert Rev Clin Immunol. 2018 Feb;14(2):137-153. doi: 10.1080/1744666X.2018.1426462. Epub 2018 Jan 23.

PMID:
29318902
10.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
11.

Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.

Pan F, Goh JW, Cutter G, Su W, Pleimes D, Wang C.

Clin Ther. 2012 Sep;34(9):1966-76. doi: 10.1016/j.clinthera.2012.07.010. Epub 2012 Aug 18.

PMID:
22906738
12.

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.

López-Gómez C, Oliver-Martos B, Pinto-Medel MJ, Suardiaz M, Reyes-Garrido V, Urbaneja P, Fernández Ó, Leyva L.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):130-7. doi: 10.1136/jnnp-2014-309932. Epub 2015 Mar 3.

13.

Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis.

Charbit H, Benis A, Geyshis B, Karussis D, Petrou P, Vaknin-Dembinsky A, Lavon I.

J Clin Neurosci. 2015 Jun;22(6):986-9. doi: 10.1016/j.jocn.2014.11.027. Epub 2015 Apr 14.

PMID:
25882258
14.

Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.

Ochi H, Feng-Jun M, Osoegawa M, Minohara M, Murai H, Taniwaki T, Kira J.

J Neurol Sci. 2004 Jul 15;222(1-2):65-73.

PMID:
15240198
15.

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.

Chiao E, Meyer K.

Curr Med Res Opin. 2009 Jun;25(6):1445-54. doi: 10.1185/03007990902876040.

PMID:
19422279
16.

Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.

van der Voort LF, Visser A, Knol DL, Oudejans CB, Polman CH, Killestein J.

Eur J Neurol. 2009 Sep;16(9):1049-52. doi: 10.1111/j.1468-1331.2009.02649.x. Epub 2009 May 22.

PMID:
19486142
17.

Beta-interferon exposure and onset of secondary progressive multiple sclerosis.

Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H; BC MS Clinic Neurologists.

Eur J Neurol. 2015 Jun;22(6):990-1000. doi: 10.1111/ene.12698. Epub 2015 Apr 6.

18.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

19.

Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment.

Malhotra S, Morcillo-Suárez C, Nurtdinov R, Rio J, Sarro E, Moreno M, Castilló J, Navarro A, Montalban X, Comabella M.

Eur J Neurol. 2013 Oct;20(10):1390-7. doi: 10.1111/ene.12193. Epub 2013 May 22.

PMID:
23700969
20.

Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS.

Gayo A, Mozo L, Suárez A, Tuñón A, Lahoz C, Gutiérrez C.

Neurology. 1999 Jun 10;52(9):1764-70.

PMID:
10371521

Supplemental Content

Support Center